XKRX
017180
Market cap26mUSD
Jul 10, Last price
1,237.00KRW
1D
1.89%
1Q
-31.66%
Jan 2017
-75.86%
IPO
-53.99%
Name
Myungmoon Pharm Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MYUNGMOON Pharm Co., Ltd. operates as a pharmaceutical enterprise, comprehensively handling the research, development, production, distribution, and commercialization of medicinal products. Its business activities extend across South Korea and into global markets. The company offers an extensive array of prescription drugs, addressing a broad spectrum of medical conditions. This range includes treatments for musculoskeletal issues like osteoarthritis, inflammation, rheumatoid arthritis, and muscle relaxation, alongside anti-infectives (antibiotics and antifungals), respiratory aids, and gastrointestinal therapeutics. Cardiovascular health is targeted with circulation agents, anti-hypertensive drugs, and antidiabetic medications. Furthermore, their specialized pharmacotherapy solutions cover narcotics, anesthetics, central nervous system agents, female hormone products, osteoporosis treatments, urogenital medications, adrenocortical hormones, oncology drugs, dermal fillers, and anti-obesity agents. Beyond prescription items, MYUNGMOON Pharm also supplies a diverse selection of over-the-counter (OTC) remedies. These encompass medications for nausea, genitourinary concerns, gum disease, liver support, parasitic infections, constipation, oral ailments, diarrhea, and general digestive health. The OTC portfolio further includes cold and flu treatments, calcium supplements, nasal sprays, multi-vitamins, eye nutrition products, eye drops, blood circulation enhancers, and topical preparations such as external skin treatments and localized pain relievers. In addition to its pharmaceutical lines, the firm markets health supplements, quasi-pharmaceuticals, and blended juice beverages. Established in 1983, MYUNGMOON Pharm Co., Ltd. maintains its primary corporate office in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||